According to Dr. Peter Dicpinigaitis, Professor of Medicine at the prestigious Albert Einstein College of Medicine in NYC one of America's top ranked medical research institutions, Algernon Pharmaceutical (CSE: AGN)'s Ifenprodil could become a "first-in-class" treatment for chronic cough.
Dr. Dicpinigaitis said earlier this month, “The NMDA receptor is a fascinating target, and Ifenprodil, if successful, would be a first-in-class treatment. I am excited about the drug’s potential not only for cough in IPF, but also for the wider refractory chronic cough population.”
Dr. Dicpinigaitis is one of the world's most respected experts on chronic cough. Click here to see his bio!
Past performance is not an indicator of future returns. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. NIA has received compensation from AGN of US$100,000 cash for a twelve-month marketing contract. This message is meant for informational and educational purposes only and does not provide investment advice.